ArticleActa neuropathologica2024
Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.
Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Foamy microglia link oxylipins to disease progression in multiple sclerosis.Nature neuroscience · 2026Article
- Donor-specific pathological features associate with genetic background, lesion type distribution, and clinical heterogeneity in multiple sclerosis.Acta neuropathologica · 2026Article
- Implementing Co-innovation to Develop an Accessible, Web-Based Exercise Program for People with Multiple Sclerosis.Archives of rehabilitation research and clinical translation · 2026Article
- From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA-A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression.Neurology international · 2026Review
- B-cell abundance in perivascular cuffs associates with local lesion activity in multiple sclerosis.Acta neuropathologica communications · 2026Article
- Co-occurrence of parkinson disease and multiple sclerosis - a critical note.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Co-occurrence of amyotrophic lateral sclerosis and multiple sclerosis: a rare but interesting association.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis.Brain communications · 2026Article
- Review
- Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis.Nature medicine · 2025Article
- Recent developments in multiple sclerosis neuropathology.Current opinion in neurology · 2025Review
- Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.Journal of neurology · 2025Review
- Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS.European journal of neurology · 2025Article
- Inflammatory microglia correlate with impaired oligodendrocyte maturation in multiple sclerosis.Frontiers in immunology · 2024Article
- Cortical CD200-CD200R and CD47-SIRPα expression is associated with multiple sclerosis pathology.Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Multiple sclerosis (MS) is a heterogeneous neurological disorder with regards to clinical presentation and pathophysiology. Here, we investigated the heterogeneity of MS by performing an exploratory factor analysis on quantitative and qualitative neuropathology data collected for 226 MS donors in the Netherlands Brain Bank autopsy cohort. Three promising dimensions were identified and subsequently validated with clinical, neuropathological, and genetic data. Dimension 1 ranged from a predominance of remyelinated and inactive lesions to extensive pathological changes, higher proportions of active and mixed lesions, and foamy microglia morphology. This pattern was positively correlated with more severe disease, the presence of B and T cells, and neuroaxonal damage. Scoring high on dimension 2 was associated with active lesions, reactive sites, and the presence of nodules. These donors had less severe disease, a specific pattern of cortical lesions, and MS risk variants in the human leukocyte antigen region, the latter indicating a connection between disease onset and this neuropathological dimension. Donors scoring high on dimension 3 showed increased lesional pathology with relatively more mixed and inactive lesions and ramified microglia morphology. This pattern was associated with longer disease duration, subpial cortical lesions, less involvement of the adaptive immune system, and less axonal damage. Taken together, the three dimensions may represent (1) demyelination and immune cell activity associated with pathological and clinical progression, (2) microglia (re)activity and possibly lesion initiation, and (3) loss of lesion activity and scar formation. Our findings highlight that a thorough understanding of the interplay between multiple pathological characteristics is crucial to understand the heterogeneity of MS pathology, as well as its association with genetic predictors and disease outcomes. The scores of donors on the dimensions can serve as an important starting point for further disentanglement of MS heterogeneity and translation into observations and interventions in living cohorts with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.